--- title: "Protara Therapeutics (TARA) news: offering" url: "https://aibio.space/companies/protara-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TARA offering news: Protara Therapeutics puts cash runway into 2027, counting $102.7 million offering. Protara Therapeutics, Inc." --- TARA Protara Therapeutics, Inc. NASDAQ · United States # Protara Therapeutics (TARA) news TARA offering news Financings · 2025-01-13 ## [Protara Therapeutics puts cash runway into 2027, counting $102.7 million offering](https://aibio.space/news/protara-therapeutics-puts-cash-runway-2027-counting-102-7-million/) Protara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Its balance sheet figure is $81.5 million at September 30, 2024, and its bladder cancer efficacy data come from a small single-arm trial. ## Latest Protara Therapeutics news We have not published a story on Protara Therapeutics yet. When there is news, it will appear here. ## Protara Therapeutics at a glance - **Ticker**: TARA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $142.5 million ### Related companies - [Bolt Biotherapeutics](https://aibio.space/companies/bolt-biotherapeutics/) NASDAQ: BOLT - [Theriva Biologics](https://aibio.space/companies/theriva-biologics/) AMEX: TOVX - [HARD TO TREAT DISEASES INC](https://aibio.space/companies/hard-to-treat-diseases/) OTC: HTDS - [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) AMEX: PTHS - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) NASDAQ: ABVC - [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) NASDAQ: RNTX - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) NASDAQ: CNSP - [Vyome Holdings](https://aibio.space/companies/vyome/) NASDAQ: HIND ### Also on NASDAQ - [Twist Bioscience](https://aibio.space/companies/twist-bioscience/) TWST - [NuCana](https://aibio.space/companies/nucana/) NCNA - [Xenon Pharmaceuticals](https://aibio.space/companies/xenon-pharmaceuticals/) XENE - [Jupiter Neurosciences](https://aibio.space/companies/jupiter-neurosciences/) JUNS - [Corbus Pharmaceuticals Holdings](https://aibio.space/companies/corbus-pharmaceuticals/) CRBP - [Medicus Pharma](https://aibio.space/companies/medicus-pharma/) MDCX ## Protara Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$42.6 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | [$31.7 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | | Net income (loss) | [-$57.4 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | [-$44.6 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | | Cash from operations | [-$56.4 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | [-$35.8 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | | Cash and equivalents | [$49.7 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026087508/) | [$162.8 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | | Short-term investments | [$105.9 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026087508/) | [$7.5 million](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $17.1 million, plus short-term investments of $125.4 million, $142.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Mixed view 2026-10-28 [Protara has 26 months of cash on paper, early data and plans that need more money](https://aibio.space/analysis/protara-cash-covers-about-26-months-paper-but-own-plans/) Protara has $142.5 million and a bladder cancer trial with small, open-label, uncontrolled interim data whose response rate fell by half between six and 12 months. Spending is rising, and the company says it will need new capital. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Protara Therapeutics Has Protara Therapeutics raised money recently? Our latest story on this, dated Jan 13, 2025: "Protara Therapeutics puts cash runway into 2027, counting $102.7 million offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/protara-therapeutics-puts-cash-runway-2027-counting-102-7-million/). What is the ticker symbol of Protara Therapeutics? Protara Therapeutics, Inc. trades under the ticker TARA on NASDAQ. Where is Protara Therapeutics listed? Protara Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1KPA. What is the SEC CIK of Protara Therapeutics? The SEC Central Index Key (CIK) for Protara Therapeutics, Inc. is 1359931. Its filings are on SEC EDGAR. How many shares does Protara Therapeutics have outstanding? 59,095,488 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Protara Therapeutics listed under? Our directory records Protara Therapeutics, Inc. under United States. What does Protara Therapeutics do? Our directory classifies Protara Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Protara Therapeutics? The ISIN recorded for Protara Therapeutics, Inc. is US74365U1079. Does aibio.space cover Protara Therapeutics? aibio.space lists Protara Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Protara Therapeutics profitable? Protara Therapeutics, Inc. reported a net loss of $57.4 million for the fiscal year ended Dec 31, 2025, and used $56.4 million of cash in operations, per its annual report to the SEC. How much does Protara Therapeutics spend on research and development? $42.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Protara Therapeutics have? $142.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Protara Therapeutics (TARA) stock news? Our latest story on Protara Therapeutics, dated Jan 13, 2025: "Protara Therapeutics puts cash runway into 2027, counting $102.7 million offering". Protara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Its balance sheet figure is $81.5 million at September 30, 2024, and its bladder cancer efficacy data come from a small single-arm trial. [Source](https://aibio.space/news/protara-therapeutics-puts-cash-runway-2027-counting-102-7-million/). How long will Protara Therapeutics's cash last? From our story of Jan 13, 2025: Protara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. [Source](https://aibio.space/news/protara-therapeutics-puts-cash-runway-2027-counting-102-7-million/). What is Protara Therapeutics's market cap? We do not publish live share prices. In its annual report, Protara Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $112.3 million as of Jun 30, 2025. ## Investor discussion: Protara Therapeutics Members talk about Protara Therapeutics (TARA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Protara Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-15 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/ea0294030-8k_protara.htm) 2. 2026-05-28 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1359931/000121390026062153/ea0292362-424b5_protara.htm) 3. 2025-12-15 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1359931/000121390025121687/ea0269478-8k_protara.htm) 4. 2025-12-04 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1359931/000121390025118304/ea026827702-424b5_protara.htm) 5. 2025-01-13 Financings Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea022745701ex99-1_protara.htm) 6. 2024-12-09 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1359931/000121390024106942/ea0224014-424b5_protara.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TARA on TradingView](https://www.tradingview.com/symbols/NASDAQ-TARA/). ## SEC filings and registration - **SEC name**: Protara Therapeutics, Inc. - **CIK**: 1359931 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: TARA (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 345 PARK AVENUE SOUTH, NEW YORK, NY, 10010 - **Phone**: 646-844-0337 - **Shares outstanding**: 59,095,488 as of 2026-08-07 (10-Q filed 2026-08-11) - **Former names**: Protara Therapeutics, Inc.; ArTara Therapeutics, Inc.; PROTEON THERAPEUTICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1359931/000121390026087508/ea0298600-10q_protara.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea0299236-8k_protara.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1359931/000121390026073184/ea0296286-8k_protara.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/ea0294030-8k_protara.htm) filed 2026-06-15 - [424B5](https://www.sec.gov/Archives/edgar/data/1359931/000121390026062153/ea0292362-424b5_protara.htm) filed 2026-05-28 - [S-3](https://www.sec.gov/Archives/edgar/data/1359931/000121390026056057/ea0289983-s3_protara.htm) filed 2026-05-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1359931/000121390026055463/ea0287944-10q_protara.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea0288581-8k_protara.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001359931), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Protara Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TARA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Protara Therapeutics, Inc. - **Ticker**: TARA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US74365U1079 - **Other listed symbols**: GETTEX:1KPA - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TARA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/protara-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Protara Therapeutics (TARA) news: offering", 2026-10-31, https://aibio.space/companies/protara-therapeutics/